Printer Friendly

PFIZER INC - Research Update.

        Pfizer's Lipitor Provides Greater Reductions in Heart Attack,
       Stroke and Cardiovascular Procedures at an Overall Cost Savings
                    Compared to Zocor, New Analysis Shows

     * Major Study Shows That One Out of Every Six Heart Attacks, Strokes and
       Cardiovascular Procedures Could be Avoided for Heart Disease Patients
       Treated With Intensive Lipitor 80mg Therapy Vs. Standard Dose Zocor

     * Even If the Current U.S. Price of Zocor Were Reduced by 50 Percent,
       Lipitor Patients Could Still Achieve the Greater Cardiovascular
       Benefits Seen in This Study at a Cost Savings for Payors

     * Dr. Peter Lindgren: "This analysis suggests that the cost of using
       Lipitor versus generic simvastatin could represent a good value for

     * Lipitor Study Further Supports New AHA/ACC Guidelines for Secondary
       Prevention-LDL-Cholesterol of Less than 100 mg/dL for all Patients With
       Coronary Heart Disease

    NEW YORK, May 16 -- Pfizer Inc said today that a new economic analysis that
compares outcomes for patients taking Lipitor to those taking Zocor shows that
Lipitor patients had greater reductions in heart attacks, strokes and
cardiovascular procedures.  This provides a cost savings for payors in long-term
hospitalizations and surgical costs.
    The economic analysis examined the results from the IDEAL (Incremental
Decrease in Endpoints Through Aggressive Lipid Lowering) trial to analyze the
cost effectiveness of treatment with Lipitor and Zocor (simvastatin) in
Sweden, where Zocor is available generically as simvastatin.  The IDEAL
patients who received Lipitor (80 mg) achieved greater reductions in heart
attacks, strokes and cardiovascular procedures compared to patients taking
standard dose Zocor (20-40 mg).
    The results also showed that one out of every six heart attacks, strokes
or cardiovascular procedures could be avoided for coronary heart disease
patients treated with intensive Lipitor therapy above and beyond those treated
with Zocor over 4.8 years.
    These results were then applied to the U.S. health care system, with two
key findings:

    * Better efficacy was achieved in patients taking Lipitor, at a better
      overall value, compared to patients on standard Zocor therapy; and

    * Patients taking Lipitor achieved greater reductions in cardiovascular
      events, and the system had overall cost savings, compared to patients
      taking Zocor at the current U.S. price, and even when Zocor was
      discounted by 50 percent.

    In the U.S., cardiovascular disease remains the nation's leading health
threat, and accounts for an estimated 500,000 recurrent heart attacks and
200,000 recurrent debilitating strokes annually.
    "The economic impact of heart attacks and strokes in the U.S. alone totals
nearly $403 billion in medical care and lost productivity annually," said Dr.
Peter Lindgren, Stockholm Health Economics.  "This analysis suggests that the
cost of using Lipitor versus generic simvastatin could represent a good value
for money."
    "Even if the current U.S. price of Zocor were reduced by 75 percent,
Lipitor patients could still achieve better cardiovascular outcomes at an
increase to payors of less than one dollar a day," said Dr. Gregg Larson, vice
president cardiovascular medical at Pfizer.  "While the economic cost of a
stroke can be exorbitant, often entailing years of rehabilitation and
supervised care the emotional impact on patients and their families is also
    The IDEAL economic analysis assessed the cost-effectiveness of preventing
cardiovascular events for patients who took intensive Lipitor therapy versus
standard dose Zocor.  The analysis compared the total cost per patient for 4.8
years in each treatment group by calculating medication costs, the cost of
hospitalizations associated with cardiovascular events and lost work days for
the U.S. and for Sweden.  The cost of Lipitor was compared to the cost of
generic simvastatin for Sweden.  For the U.S., the cost of Lipitor was
compared to Zocor in three scenarios, including:

    * Lipitor compared to the current U.S. price of Zocor (simvastatin);

    * Lipitor compared to a 50% reduction in the current U.S. price of Zocor;

    * Lipitor compared to a 75% reduction in the current U.S. price of Zocor.

    "IDEAL, which is one of a limited number of head to head statin therapy
trials showed that patients using intensive atorvastatin therapy compared with
standard dose simvastatin suffered fewer cardiovascular events.  The findings
in IDEAL, along with other positive studies of intensive atorvastatin therapy
against active treatment comparitors such as AVERT, PROVE-IT, REVERSAL and
ALLIANCE, indicate that all statin therapy in not alike," said Dr. Michael
Koren, director of non-invasive cardiology at Memorial Hospital in
Jacksonville, Florida.  "Switching patients from atorvastatin to other less
effective drugs could have negative health implications for patients.  The
IDEAL pharmacoeconomic analysis makes the case that drug cost savings from use
of generic statins may be largely offset by higher patients care and indirect
    The results were presented at the annual American Heart Association
Quality of Care and Outcomes Research Meeting in Washington, D.C., and a
summary of the data was published in the current issue of "Circulation."
    The newly announced American Heart Association (AHA) and American College
of Cardiology (ACC) guidelines on secondary prevention further support LDL
reduction.  The new guidelines recommend that LDL-cholesterol should be less
than 100 mg/dL for all patients with CHD and other forms of atherosclerosis
vascular disease.  In the IDEAL study, patients treated with Lipitor achieved
average LDL-cholesterol levels of 81 mg/dL which was significantly lower than
patients taking Zocor, who had an average LDL-cholesterol level of 104 mg/dL.
    Lipitor is the most prescribed cholesterol-lowering therapy in the world,
with nearly 115 million patient-years of experience.
    Lipitor is a prescription drug.  It is used in patients with multiple risk
factors for heart disease such as family history, high blood pressure, age,
low HDL or smoking to reduce the risk of heart attack and stroke.  When diet
and exercise alone are not enough, Lipitor is used along with a low-fat diet
and exercise to lower cholesterol.
    Lipitor is also used in patients with type 2 diabetes and at least one
other risk factor for heart disease such as high blood pressure, smoking or
complications of diabetes, including eye disease and protein in urine, to
reduce the risk of heart attack and stroke.
    Lipitor is not for everyone.  It is not for those with liver problems.
And it is not for women who are nursing, pregnant or may become pregnant.
    If you take Lipitor, tell your doctor if you feel any new muscle pain or
weakness.  This could be a sign of rare but serious muscle side effects.  Tell
your doctor about all medications you take.  This may help avoid serious drug
interactions.  Your doctor should do blood tests to check your liver function
before and during treatment and may adjust your dose.  The most common side
effects are gas, constipation, stomach pain and heartburn.  They tend to be
mild and often go away.
    For additional product information, visit

SOURCE  Pfizer Inc
    -0-                             05/16/2006
    /CONTACT: Vanessa Aristide of Pfizer Inc, +1-212-733-3784/
    /Company News On-Call: Pfizer's press releases are available through PR
Newswire's Company News On-Call service on PRN's Web Site.  Visit
    /Photo:  A free corporate logo to accompany this story is available
immediately via Wieck Photo Database to any media with telephoto receiver
or electronic darkroom, PC or Macintosh, that can accept overhead
transmissions.  To retrieve a logo, please call 972-392-0888./
    /Company News On-Call:
    /Web site:


COPYRIGHT 2006 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire UK Disclose
Date:May 16, 2006
Previous Article:VENUE SOLUTIONS PLC - Placing.
Next Article:ELECTRONIC DATA SYSTEMS CORP - EDS Realigns Executive Team.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters